Company Statement: Sanofi-aventis to acquire Genzyme for $74.00 in cash per share
MLex Summary: French pharmaceutical giant Sanofi-aventis and USÂ biotechnology company Genzyme have announced that they have entered into a definitive agreement under which Sanofi-aventis will acquire Genzyme. The acquisition has already received...To view the full article, register now.
Already a subscriber? Click here to view full article